CoVPN 3006: T Cell and Antibody Profiles in Young Adults with Varied COVID-19 Exposures

209 participants from the CoVPN 3006 vaccine trial provided blood samples for profiling T cell receptor (TCR) repertoires and anti-SARS-CoV-2 antibody responses. The dataset includes measurements from pre-exposure, post-vaccination, and post-breakthrough infection timepoints, enabling analysis of hybrid immunity. A key methodological feature is the protocol for recovering TCR sequences from frozen blood clots, allowing paired cellular and humoral immune data from a single blood sample.

Use Cases

• Comparing TCR repertoire breadth and antibody potency between vaccination-after-infection and infection-after-vaccination exposures.
• Investigating correlations between nasal viral load/shedding duration and specific immune parameters.
• Validating protocols for TCR sequencing from remnant coagulated blood material.
• Modeling the impact of hybrid immunity on disease severity and viral kinetics.

Strengths

• Includes paired TCR repertoire and antibody neutralization data from 209 participants, a substantial cohort for immunological studies.
• Features longitudinal sampling across three key immunological timepoints (pre-exposure, post-vaccination, post-breakthrough).
• Data is associated with a published study in Frontiers in Immunology, providing scientific context.

Limitations

• Column names and a precise row count are not provided, limiting assessment of data structure and granularity.
• The dataset is large (approximately 9.66 GB in a ZIP file), which may pose storage and processing challenges.
• Specific demographic or clinical details about the 'young adult' cohort are not enumerated in the provided metadata.

Provenance

Source

Subset of participants from the COVID-19 Prevention Network (CoVPN) vaccine trial 3006, led by author Andrew Fiore-Gartland.

Collection Method

TCR repertoires were sequenced from genomic DNA recovered from frozen blood clots; antibody responses were measured from serum.

Time Range

Covers periods before exposure, after vaccination, and after breakthrough SARS-CoV-2 infection.

Freshness

Last updated on 2026-03-19.

Geography

Multi-center cohort, but specific locations are not detailed.